X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Strides Arcolab with GSK Pharma - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

STRIDES SHASUN LTD vs GSK PHARMA - Comparison Results

STRIDES SHASUN LTD    Change

Strides Arcolab is an Indian pharmaceutical company headquartered at Bangalore. The company is primarily involved in two businesses notably the pharma business and the specialized sterile products business branded as Agila. This segment focuses large... More

GSK PHARMA 
   Change

GSK Pharma is one of the leading MNC pharma companies in the Indian market. It is a 50.7% subsidiary of GlaxoSmithKline Plc, one of the world's largest pharma companies. GSK Pharma's product portfolio boasts of some of the leading brands like Augment... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    STRIDES SHASUN LTD GSK PHARMA STRIDES SHASUN LTD/
GSK PHARMA
 
P/E (TTM) x 44.0 66.4 66.2% View Chart
P/BV x 1.1 13.4 8.2% View Chart
Dividend Yield % 0.9 2.2 42.0%  

Financials

 STRIDES SHASUN LTD   GSK PHARMA
EQUITY SHARE DATA
    STRIDES SHASUN LTD
Mar-17
GSK PHARMA
Mar-18
STRIDES SHASUN LTD/
GSK PHARMA
5-Yr Chart
Click to enlarge
High Rs1,2752,760 46.2%   
Low Rs9182,040 45.0%   
Sales per share (Unadj.) Rs389.6339.0 114.9%  
Earnings per share (Unadj.) Rs28.041.4 67.5%  
Cash flow per share (Unadj.) Rs48.945.9 106.5%  
Dividends per share (Unadj.) Rs4.5035.00 12.9%  
Dividend yield (eoy) %0.41.5 28.1%  
Book value per share (Unadj.) Rs303.1242.9 124.8%  
Shares outstanding (eoy) m89.4284.70 105.6%   
Bonus/Rights/Conversions ESOP--  
Price / Sales ratio x2.87.1 39.8%   
Avg P/E ratio x39.257.9 67.6%  
P/CF ratio (eoy) x22.452.3 42.9%  
Price / Book Value ratio x3.69.9 36.6%  
Dividend payout %16.184.5 19.0%   
Avg Mkt Cap Rs m98,036203,280 48.2%   
No. of employees `0005.8NA-   
Total wages/salary Rs m5,8815,234 112.4%   
Avg. sales/employee Rs Th6,005.9NM-  
Avg. wages/employee Rs Th1,014.0NM-  
Avg. net profit/employee Rs Th431.2NM-  
INCOME DATA
Net Sales Rs m34,83428,715 121.3%  
Other income Rs m1,686545 309.1%   
Total revenues Rs m36,52029,260 124.8%   
Gross profit Rs m6,4285,059 127.1%  
Depreciation Rs m1,872380 492.5%   
Interest Rs m2,2692 113,465.0%   
Profit before tax Rs m3,9735,222 76.1%   
Minority Interest Rs m00-   
Prior Period Items Rs m40-   
Extraordinary Inc (Exp) Rs m-1,006178 -565.0%   
Tax Rs m4701,892 24.8%   
Profit after tax Rs m2,5013,508 71.3%  
Gross profit margin %18.517.6 104.7%  
Effective tax rate %11.836.2 32.7%   
Net profit margin %7.212.2 58.8%  
BALANCE SHEET DATA
Current assets Rs m38,16521,815 175.0%   
Current liabilities Rs m30,40215,999 190.0%   
Net working cap to sales %22.320.3 110.0%  
Current ratio x1.31.4 92.1%  
Inventory Days Days7764 121.6%  
Debtors Days Days10419 559.1%  
Net fixed assets Rs m37,63912,475 301.7%   
Share capital Rs m894847 105.6%   
"Free" reserves Rs m26,21019,726 132.9%   
Net worth Rs m27,10520,573 131.7%   
Long term debt Rs m16,3776 272,951.7%   
Total assets Rs m81,16839,475 205.6%  
Interest coverage x2.82,612.0 0.1%   
Debt to equity ratio x0.60 207,180.1%  
Sales to assets ratio x0.40.7 59.0%   
Return on assets %5.98.9 66.1%  
Return on equity %9.217.1 54.1%  
Return on capital %12.126.2 45.9%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m13,465564 2,387.4%   
Fx outflow Rs m4,0767,429 54.9%   
Net fx Rs m9,389-6,865 -136.8%   
CASH FLOW
From Operations Rs m2,8814,728 60.9%  
From Investments Rs m-7,051-1,042 676.8%  
From Financial Activity Rs m3,382-3,066 -110.3%  
Net Cashflow Rs m-788620 -127.1%  

Share Holding

Indian Promoters % 27.7 0.0 -  
Foreign collaborators % 0.0 50.7 -  
Indian inst/Mut Fund % 37.8 10.2 370.6%  
FIIs % 8.6 23.8 36.1%  
ADR/GDR % 0.0 0.0 -  
Free float % 25.9 15.4 168.2%  
Shareholders   56,241 102,036 55.1%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare STRIDES SHASUN LTD With:   CADILA HEALTHCARE  TTK HEALTHCARE  SHASUN PHARMA  BIOCON LTD  J.B.CHEMICALS  

Compare STRIDES SHASUN LTD With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Slumps Over 275 Points; Realty and Banking Stocks Witness Selling(Closing)

After trading on a volatile note throughout the day, share markets in India witnessed selling pressure during the closing hours and ended the day in red.

Related Views on News

STRIDES SHASUN LTD Announces Quarterly Results (1QFY19); Net Profit Down 57.5% (Quarterly Result Update)

Aug 10, 2018 | Updated on Aug 10, 2018

For the quarter ended June 2018, STRIDES SHASUN LTD has posted a net profit of Rs 38 m (down 57.5% YoY). Sales on the other hand came in at Rs 7 bn (down 21.2% YoY). Read on for a complete analysis of STRIDES SHASUN LTD's quarterly results.

GSK PHARMA Announces Quarterly Results (1QFY19); Net Profit Up 235.3% (Quarterly Result Update)

Jul 26, 2018 | Updated on Jul 26, 2018

For the quarter ended June 2018, GSK PHARMA has posted a net profit of Rs 886 m (up 235.3% YoY). Sales on the other hand came in at Rs 7 bn (up 21.2% YoY). Read on for a complete analysis of GSK PHARMA's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

More Views on News

Most Popular

Is It the Right Time to Buy Pharma Stocks Now?(The 5 Minute Wrapup)

Sep 12, 2018

Is the pharma sector poised for a comeback? Is the worst over? I believe so.

Want Bigger Returns Than You Thought Possible? This is Where You Should Look(Profit Hunter)

Sep 12, 2018

Richa has discovered the single most profitable opportunity in the market - read on to discover more...

Are You Blindly Investing In Equities? Read This...(Outside View)

Sep 11, 2018

PersonalFN explains how blindly investing in equities can prove hazardous to your wealth and health.

Investors Are Redeeming From Equity Mutual Funds Now. Should You?(Outside View)

Sep 12, 2018

PersonalFN elucidates if you should redeem from equity mutual fund now, and the approach to follow before you decide to sell mutual funds.

Outperformance of Strong Established Brands in the Indian Stock market(Chart Of The Day)

Sep 14, 2018

Strong Well established Indian Brands have comfortably outperformed the index in the decade post the global financial crisis.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

STRIDES SHASUN LTD SHARE PRICE


Sep 21, 2018 (Close)

TRACK STRIDES SHASUN LTD

  • Track your investment in STRIDES SHASUN LTD with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON STRIDES SHASUN LTD

STRIDES SHASUN LTD 8-QTR ANALYSIS

COMPARE STRIDES SHASUN LTD WITH

MARKET STATS